Terms: = Skin cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Treatment
171 results:
1. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
[TBL] [Abstract] [Full Text] [Related]
2. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
Zhang D; Benedikt Westphalen C; Quante M; Waldschmidt DT; Held S; Kütting F; Dorman K; Heinrich K; Weiss L; Boukovala M; Haas M; Boeck S; Heinemann V; Probst V
Eur J Cancer; 2024 Apr; 201():113926. PubMed ID: 38401449
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol.
Fujimura T; Yoshino K; Nakamura M; Kato H; Ito T; Maekawa T; Fujisawa Y; Matsushita S; Amagai R; Yamazaki E; Takahashi M; Tamabuchi E; Hashimoto A; Kambayashi Y; Yamazaki N; Miyata T; Asano Y
Exp Dermatol; 2024 Jan; 33(1):e14976. PubMed ID: 37946551
[TBL] [Abstract] [Full Text] [Related]
4. Digital spatial profiling of melanoma shows cd95 expression in immune cells is associated with resistance to immunotherapy.
Martinez-Morilla S; Moutafi M; Fernandez AI; Jessel S; Divakar P; Wong PF; Garcia-Milian R; Schalper KA; Kluger HM; Rimm DL
Oncoimmunology; 2023; 12(1):2260618. PubMed ID: 37781235
[TBL] [Abstract] [Full Text] [Related]
5. Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL.
Tam C; Pinilla-Ibarz J; Castillo CG; Fenili AC; Huntley K; Karakus V; Mattar M; Miroli MA; Moura C; Pavlovsky M; Piotrowski F; Šimkovič M; Stilgenbauer S
Blood Adv; 2023 Nov; 7(22):6819-6828. PubMed ID: 37722356
[TBL] [Abstract] [Full Text] [Related]
6. Postoperative Echography for Optimization of Radiation Dosimetry in Patients with Uveal Melanoma Treated with Plaque Brachytherapy.
Binkley EM; King BA; Hyer DE; Javed A; Milhem MM; Hinz CJ; Mott SL; Boldt HC
Ophthalmol Retina; 2023 Jul; 7(7):620-627. PubMed ID: 36822323
[TBL] [Abstract] [Full Text] [Related]
7. PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity.
Gu Y; Lin X; Dong Y; Wood G; Seidah NG; Werstuck G; Major P; Bonert M; Kapoor A; Tang D
J Exp Clin Cancer Res; 2023 Jan; 42(1):2. PubMed ID: 36588164
[TBL] [Abstract] [Full Text] [Related]
8. Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma.
Cartun Z; Kunz WG; Heinzerling L; Tomsitz D; Guertler A; Westphalen CB; Ricke J; Weir W; Unterrainer M; Mehrens D
JAMA Dermatol; 2022 Dec; 158(12):1387-1393. PubMed ID: 36260321
[TBL] [Abstract] [Full Text] [Related]
9. PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta-analysis.
He R; Zhao X; Liu J; Zhou Y; Zhang X; Cheng F
Medicine (Baltimore); 2022 Oct; 101(41):e30561. PubMed ID: 36254050
[TBL] [Abstract] [Full Text] [Related]
10. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N
Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320
[TBL] [Abstract] [Full Text] [Related]
11. The contribution of rare copy number variants in fas toward pathogenesis of autoimmune lymphoproliferative syndrome.
Jevtich K; Price S; Similuk M; Kulm E; Yan J; Setzer M; Jamal L; Franco LM; Ghosh R; Walkiewicz M; Rao VK
Blood Adv; 2022 Jul; 6(13):3974-3978. PubMed ID: 35476126
[TBL] [Abstract] [Full Text] [Related]
12. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.
Chen CB; Wang CW; Chung WH
Methods Mol Biol; 2022; 2486():37-54. PubMed ID: 35437717
[TBL] [Abstract] [Full Text] [Related]
13. Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot skin Reaction: A Single-Arm, Open-Label Phase I/II Study (DGA Study).
Yamamoto K; Nishiyama S; Kunisada M; Iida M; Ito T; Ioroi T; Makimoto H; Omura T; Harada K; Fujisawa M; Nishigori C; Yano I
Oncologist; 2022 May; 27(5):e384-e392. PubMed ID: 35285503
[TBL] [Abstract] [Full Text] [Related]
14. Immunotherapy-induced isolated ACTH deficiency in cancer therapy.
Iglesias P; Peiró I; Biagetti B; Paja-Fano M; Cobo DA; García Gómez C; Mateu-Salat M; Genua I; Majem M; Riudavets M; Gavira J; Lamas C; Fernández Pombo A; Guerrero-Pérez F; Villabona C; Cabezas Agrícola JM; Webb SM; Díez JJ
Endocr Relat Cancer; 2021 Oct; 28(12):783-792. PubMed ID: 34609950
[TBL] [Abstract] [Full Text] [Related]
15. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.
Dent P; Booth L; Poklepovic A; Kirkwood JM
Pigment Cell Melanoma Res; 2022 Jan; 35(1):66-77. PubMed ID: 34482636
[TBL] [Abstract] [Full Text] [Related]
16. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract] [Full Text] [Related]
17. High ROS Production by Celecoxib and Enhanced Sensitivity for Death Ligand-Induced Apoptosis in Cutaneous SCC Cell Lines.
Zhu J; May S; Ulrich C; Stockfleth E; Eberle J
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807213
[TBL] [Abstract] [Full Text] [Related]
18. The effect of 0.5% topical timolol cream on regression of superficial infantile haemangioma in the involuting phase: a prospective, randomized, self-controlled study.
Ying H; Han Y; Chen Z; Yu Z; Chang L; Ma G; Chen Q; Chang S; Qiu Y; Lin X
Eur J Dermatol; 2020 Oct; 30(5):591-595. PubMed ID: 33185527
[TBL] [Abstract] [Full Text] [Related]
19. Medical Immunosuppression and Outcomes in Cutaneous Melanoma: A Population-Based Cohort Study.
Bogach J; Wright FC; Austin J; Cheng SY; Diong C; Sutradhar R; Baxter NN; Look Hong NJ
Ann Surg Oncol; 2021 Jun; 28(6):3302-3311. PubMed ID: 33067747
[TBL] [Abstract] [Full Text] [Related]
20. Long-term Oncologic Outcomes of Immediate Breast Reconstruction vs Conventional Mastectomy Alone for Breast cancer in the Setting of Neoadjuvant Chemotherapy.
Wu ZY; Kim HJ; Lee JW; Chung IY; Kim JS; Lee SB; Son BH; Eom JS; Kim SB; Jung KH; Gong G; Kim HH; Ahn SH; Ko B
JAMA Surg; 2020 Dec; 155(12):1142-1150. PubMed ID: 33052412
[TBL] [Abstract] [Full Text] [Related]
[Next]
